Back to Search
SUSAN IVY, MD
MD
Pediatric Hematology & Oncology Physician
NPI: 1972681120Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
MD17326(DC)
Research & Publications (20)
Water-soluble prodrugs of an Aurora kinase inhibitor.
PMID 19186057·Bioorg Med Chem Lett·2009
4-observational
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
PMID 18414865·Cancer Chemother Pharmacol·2009
3-trial
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
PMID 18670776·Cancer Chemother Pharmacol·2009
3-trial
2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
PMID 19646866·Bioorg Med Chem Lett·2009
7-preclinical
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
PMID 19384685·J Biopharm Stat·2009
8-other
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
PMID 18235115·J Clin Oncol·2008
3-trial
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
PMID 19047126·Clin Cancer Res·2008
3-trial
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
PMID 18519777·Clin Cancer Res·2008
3-trial
Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians.
PMID 18398754·Leuk Lymphoma·2008
8-other
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
PMID 18235116·J Clin Oncol·2008
3-trial
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
PMID 17363531·Clin Cancer Res·2007
3-trial
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
PMID 17404095·Clin Cancer Res·2007
7-preclinical
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
PMID 17363534·Clin Cancer Res·2007
3-trial
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
PMID 17363533·Clin Cancer Res·2007
3-trial
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
PMID 17363532·Clin Cancer Res·2007
3-trial
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
PMID 16133531·Cancer Chemother Pharmacol·2006
3-trial
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
PMID 15942626·Br J Cancer·2005
3-trial
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions.
PMID 15895233·Cancer Chemother Pharmacol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 111 MICHIGAN AVE NW
WASHINGTON, DC 20010 - Phone
- (202) 884-2140
Quick Facts
- NPI
- 1972681120
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile